• Something wrong with this record ?

Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

SS. Gholami, FEF. Azar, A. Rezapour, M. Tajdini,

. 2019 ; 24 (6) : 967-975. [pub] -

Language English Country United States

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Systematic Review

E-resources Online Full text

NLK ProQuest Central from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2005-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-01-01 to 1 year ago

Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20015864
003      
CZ-PrNML
005      
20201119104844.0
007      
ta
008      
201012s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10741-019-09811-3 $2 doi
035    __
$a (PubMed)31179517
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gholami, Saeed Sheikh $u Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
245    10
$a Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review / $c SS. Gholami, FEF. Azar, A. Rezapour, M. Tajdini,
520    9_
$a Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
650    _2
$a koronární bypass $x ekonomika $x metody $7 D001026
650    _2
$a nemoci koronárních tepen $x farmakoterapie $x psychologie $x chirurgie $7 D003324
650    _2
$a analýza nákladů a výnosů $x metody $7 D003362
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a koronární angioplastika $x ekonomika $x metody $7 D062645
650    _2
$a kvalitativně upravené roky života $7 D019057
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Argentina $x epidemiologie $7 D001118
651    _2
$a Rakousko $x epidemiologie $7 D001317
651    _2
$a Brazílie $x epidemiologie $7 D001938
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Anglie $x epidemiologie $7 D004739
651    _2
$a Mexiko $x epidemiologie $7 D008800
651    _2
$a Nizozemsko $x epidemiologie $7 D009426
651    _2
$a Švýcarsko $x epidemiologie $7 D013557
651    _2
$a Spojené státy americké $x epidemiologie $7 D014481
651    _2
$a Wales $x epidemiologie $7 D014852
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Azar, Farbod Ebadi Fard $u Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. dr_febadi@yahoo.com.
700    1_
$a Rezapour, Aziz $u Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
700    1_
$a Tajdini, Masih $u Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
773    0_
$w MED00007617 $t Heart failure reviews $x 1573-7322 $g Roč. 24, č. 6 (2019), s. 967-975
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31179517 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201012 $b ABA008
991    __
$a 20201119104841 $b ABA008
999    __
$a ok $b bmc $g 1584291 $s 1106032
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 24 $c 6 $d 967-975 $e - $i 1573-7322 $m Heart failure reviews $n Heart Fail Rev $x MED00007617
LZP    __
$a Pubmed-20201012

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...